Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2B | P29275 | 20/20 | 0.58 |
| ▸ | ADORA1 | P30542 | 9/20 | 0.54 |
| ▸ | ADORA3 | P0DMS8 | 7/20 | 0.54 |
| ▸ | ADORA2A | P29274 | 7/20 | 0.54 |
| ▸ | PLK4 | O00444 | 1/20 | 0.52 |
| ▸ | CDK2 | P24941 | 1/20 | 0.52 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.52 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.52 |
| ▸ | PLK3 | Q9H4B4 | 1/20 | 0.52 |
| ▸ | CSNK1G3 | Q9Y6M4 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1082117 | 0.95 | ADORA2B (0.53) | ADORA2BADORA1ADORA3ADORA2APLK4 | |
| SCHEMBL1064680 | 0.94 | ADORA2B (0.64) | ADORA2BADORA1ADORA3ADORA2APLK4 | |
| SCHEMBL4408541 | 0.92 | ADORA2B (0.62) | ADORA2BADORA1ADORA3ADORA2APLK4 | |
| SCHEMBL1065977 | 0.91 | ADORA2B (0.60) | ADORA2BADORA1ADORA3ADORA2APLK4 | |
| SCHEMBL1065691 | 0.86 | ADORA2B (0.60) | ADORA2BADORA1ADORA3ADORA2APLK4 | |
| SCHEMBL1065695 | 0.85 | ADORA2B (0.58) | ADORA2BADORA1ADORA3ADORA2A | |
| SCHEMBL4405238 | 0.84 | ADORA2B (0.58) | ADORA2BADORA1ADORA3ADORA2A | |
| SCHEMBL1065954 | 0.84 | ADORA2B (0.59) | ADORA2BADORA1ADORA3ADORA2APLK4 | |
| SCHEMBL4407382 | 0.84 | ADORA2B (0.59) | ADORA2BADORA1ADORA3ADORA2APLK4 | |
| SCHEMBL1064628 | 0.83 | ADORA2B (0.62) | ADORA2BADORA1ADORA3ADORA2APLK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2268641-B1 | HETEROCYCLIC COMPOUNDS AS ADENOSINE RECEPTOR ANTAGONIST | ADVINUS THERAPEUTICS PVT LTD (IN) | 2014-09-03 | — | — | EP | disclosed |
| US-8252797-B2 | Heterocyclic compounds as adenosine receptor antagonist | ADVINUS THERAPEUTICS PVT. LTD. (IN) | 2012-08-28 | — | — | US | disclosed |
| US-20090298744-A1 | HETEROCYCLIC COMPOUNDS AS ADENOSINE RECEPTOR ANTAGONIST | ADVINUS THERAPEUTICS PVT. LTD. (IN) | 2009-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298744-A1 | HETEROCYCLIC COMPOUNDS AS ADENOSINE RECEPTOR ANTAGONIST | ADORA2A, ADORA3, ADORA1 | ADORA2B 4/4885ADORA1 3/4885ADORA3 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.